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Abstract
Objective: To explore the potential of deep HIV-1 sequencing for adding clinically relevant information relative to viral
population sequencing in heavily pre-treated HIV-1-infected subjects.
Methods: In a proof-of-concept study, deep sequencing was compared to population sequencing in HIV-1-infected
individuals with previous triple-class virological failure who also developed virologic failure to deep salvage therapy
including, at least, darunavir, tipranavir, etravirine or raltegravir. Viral susceptibility was inferred before salvage therapy
initiation and at virological failure using deep and population sequencing genotypes interpreted with the HIVdb, Rega and
ANRS algorithms. The threshold level for mutant detection with deep sequencing was 1%.
Results: 7 subjects with previous exposure to a median of 15 antiretrovirals during a median of 13 years were included.
Deep salvage therapy included darunavir, tipranavir, etravirine or raltegravir in 4, 2, 2 and 5 subjects, respectively. Self-
reported treatment adherence was adequate in 4 and partial in 2; one individual underwent treatment interruption during
follow-up. Deep sequencing detected all mutations found by population sequencing and identified additional resistance
mutations in all but one individual, predominantly after virological failure to deep salvage therapy. Additional genotypic
information led to consistent decreases in predicted susceptibility to etravirine, efavirenz, nucleoside reverse transcriptase
inhibitors and indinavir in 2, 1, 2 and 1 subject, respectively. Deep sequencing data did not consistently modify the
susceptibility predictions achieved with population sequencing for darunavir, tipranavir or raltegravir.
Conclusions: In this subset of heavily pre-treated individuals, deep sequencing improved the assessment of genotypic
resistance to etravirine, but did not consistently provide additional information on darunavir, tipranavir or raltegravir
susceptibility. These data may inform the design of future studies addressing the clinical value of minority drug-resistant
variants in treatment-experienced subjects.
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Introduction
The rate of virological failure of the 3 original drug classes is
low, but not negligible, and does not appear to diminish over time
from starting antiretroviral therapy.[1] If this trend continues,
many patients will require newer drugs to maintain viral
suppression and accurate resistance tests will be needed to guide
clinical management. Deep HIV-1 sequencing (454 Life Sciences/
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19461Roche Diagnostics) could potentially improve genotypic resistance
assessments because it detects the same range of mutants than
Sanger viral population sequencing, but with higher sensitivity [2].
Studies have shown that pre-existing minority drug-resistant
mutants increase the risk of virological failure to first-line
antiretroviral therapy with non-nucleoside reverse transcriptase
inhibitors (NNRTIs) [3,4,5,6,7]. Conversely, low-frequency drug-
resistant variants do not affect virological outcomes of first-line
therapy including drugs with high genetic barrier, like ritonavir-
boosted protease inhibitors (PIr) [8]. Whereas most studies
addressing the role of minority variants have been performed in
antiretroviral-naı ¨ve subjects [2,3,4,5,6,7,9,10,11,12,13], less infor-
mation exists on the clinical significance of minority mutants in
antiretroviral-experienced individuals. [14,15,16]
It is particularly uncertain if ultrasensitive genotypic tests could
provide clinically relevant information in heavily pre-treated HIV-
1-infected subjects beyond that provided by standard population
sequencing genotypic tests. On one hand, detection of additional
minority drug-resistant mutants could improve the assessment of
viral susceptibility to drugs with intermediate or high drug genetic
barrier. On the other hand, the presence of extensive drug
resistance could compromise the ability of deep sequencing to add
relevant genotypic information to that already obtained with
population sequencing, particularly when alternative treatment
options are severely limited. Moreover, mutant fixation during
virological failure in the presence of ART pressure could potentially
complicate the detection of additional low-frequency variants [16].
We therefore sought to explore the potential of deep sequencing
to provide additional, clinically relevant genotypic information
that could be used to improve treatment decisions in heavily pre-
treated HIV-1-infected subjects, relative to population sequencing.
Methods
Subjects
This proof-of-concept observational study included HIV-1-
infected adults with previous virological failure (VF) to protease
inhibitors (PIs), nucleos(t)ide (NRTIs) and non-nucleoside reverse
transcriptase inhibitors (NNRTIs), who developed virological
failure to deep salvage therapy including, at least, darunavir,
tipranavir, etravirine or raltegravir. Virological failure was defined
as the presence of HIV-1 RNA levels .200 copies/mL 24 weeks
after salvage therapy initiation or beyond. Adherence was self-
reported by the patient and collected from medical charts.
Adequate adherence was defined as intake of all medication
doses. Partial adherence was defined as the presence of missed
doses during treatment. Treatment interruption meant the
complete interruption of therapy during follow-up. The Institu-
tional Review Board of the Hospital Universitari Germans Trias i
Pujol, Badalona, Spain, approved the study; participants provided
written informed consent for retrospective sample testing.
HIV RNA extraction and reverse transcription
HIV-1 RNA was extracted from 1 mL of plasma within 4 weeks
before initiation of deep salvage therapy (baseline) and at virological
failure (QIAamp UltraSens Virus Kit
TM, QIAGEN, Valencia, CA).
Three One-Step RT-PCRs (SuperScriptH III One-Step RT-PCR
System with PlatinumH Taq High Fidelity, Invitrogen, Carlsbad,
CA) were performed in parallel per each sample. Primers used were
1571-L23 (HXB2: 1417R1440) 59-ATT TCT CCT ACT GGG
ATA GGT GG-39 and 5464-L27 (HXB2: 5464R5438) 59-CCT
TGT TAT GTC CTG CTT GAT ATT CAC-39. Cycling
conditions were: 30 min. at 52uC, 2 min. at 94uC; 30 sec. at
94uC, 30 sec. at 56uC, 4 min. at 68uC, for 20 cycles; followed by 5
min. at 68uC. Triplicate RT-PCR products were pooled, column-
purified (QIAquick PCR Purification Kit, QIAGEN, Valencia, CA)
and used for both viral population and deep HIV-1 sequencing.
Viral population genotyping
Triplicate nested PCRs were performed in parallel (PlatinumH
Taq DNA Polymerase High Fidelity, Invitrogen, Carlsbad, CA)
with primers 2084-U26 (HXB2: 2084R2109) 59-ATT TTT TAG
GGA AGA TCT GGC CTT CC-39 and 5456-L26 (HXB2:
5456R5431) 59-TGT CCT GCT TGA TAT TCA CAC CTA
GG-39. Cycling conditions were: 2 min. at 94uC; 30 sec. at 94uC,
30 sec. at 56uC, 4 min. at 68uC, for 20 cycles; followed by 5 min.
at 68uC. Nested PCR products were pooled and column-purified.
Protease (PR), reverse transcriptase (RT) and integrase (IN) were
sequenced in-house (BigDye v3.1, Applied Biosystems, Foster City,
CA, USA) and resolved by capillary electrophoresis (ABI 7000,
Foster City, CA, USA).
Deep HIV-1 sequencing
Pooled purified RT-PCR products were used as template to
generate eight overlapping amplicons covering PR and RT and 3
amplicons covering codons 51 to 215 in IN. Each codon was
interrogated by at least 2 independent amplicons, which were
generated in triplicate during 20 cycles of PCR amplification
(PlatinumH Taq DNA Polymerase High Fidelity, Invitrogen,
Carlsbad, CA) followed by pooling and purification of triplicate
PCR products (QIAquick PCR Purification Kit, QIAGEN,
Valencia, CA). PCR reactions were pooled and purified using the
Agencourt AMPure Kit (Beckman Coulter, Benried, Germany) to
eliminate primer-dimers. The number of molecules was quantified
by fluorometry (Quant-iT PicoGreen dsDNA assay kit, Invitrogen,
Carlsbad, CA). When amplicon concentrations were below 5 ng/
mL, amplicon size and primer-dimer content were analysed by
spectrometry using BioAnalyzer (Agilent Technologies Inc., Santa
Clara, CA). Emulsion PCR was carried out as in [17]. Amplicon
Sequencing was performed at 454 Life Sciences, Branford,
Connecticut, USA, using a Genome Sequencer FLX. Sequences
were extracted and aligned against a consensus sequence from all
the reads for eachsequences region.Clonal sequences resultingwith
,90% similarity with the consensus sequence were discarded.
Sequencing errors in homopolymeric regions were manually
inspected and corrected. Sequences that included a stop codon
were removed. Unique sequences (haplotypes) were identified and
quantified. The frequency of mutants with a Stanford HIV
Database [18] score . 5 was determined.
Using a conservative approach, only mutations present in $ 1%
of the virus population where considered in this study. An in-house
analysis of 992 pNL43 clonal sequences obtained by deep
sequencing under the same PCR conditions used to generate
patient samples showed a mean (SD) nucleotide mismatch rate of
0.07% (0.13%), which is almost identical to previous reports [14]
and corresponds to a variability rate of 1.69610
-5, within the
range of the expected PCR error. The mean (SD) error rate for
any aminoacid mismatch was 0.14% (0.19%), but the mean (SD)
error rate for actual drug resistance mutations was 0.03% (0.07%).
The 99
th percentile of mismatches would establish the threshold
for nucleotide errors in 0.61% and the limit for identifying true
drug resistance mutations in 0.20%.
Assessment of discrepancies between population and
deep sequencing
Genotypes were interpreted with the HIVdb v6.0.8 [18], Rega
v8.0.2 [19] and ANRS v18 [20] algorithms. Only mutations with a
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included in the analysis. Viral susceptibility to each drug was
classified as ‘‘Sensitive’’, ‘‘Intermediate’’ or ‘‘Resistant’’. Sixty-
three paired drug susceptibility predictions (each pair including
population and deep sequencing genotypic data) were evaluated
per subject and timepoint, 20 for ANRS, 21 for HIVdb v6.0.8 and
22 for Rega v8.0.2.
Results
Subjects
The study included 7 individuals, 2 of them women, with
previous exposure to a median of 15 antiretrovirals during a
median of 13 years. Their median (interquartilic range, IQR) age
was 44 (39; 49) years. The median (IQR) year of HIV diagnosis
was 1988 (1985; 1994). Median (IQR) HIV-1 RNA levels and
CD4 counts were, respectively, 110,600 (46,550; 370,000) copies/
mL and 50 (12; 126) cells/mm
3 at baseline; and 36,700 (2,895;
205,000) copies/mL and 150 (27; 247) cells/mm
3 at virological
failure. Median (IQR) nadir CD4 counts were 14 (1; 152) cells/
mm
3. Deep salvage therapy included darunavir, tipranavir,
etravirine or raltegravir in 4, 2, 2 and 5 subjects, respectively.
(Table S1) Treatment adherence was adequate in 4 individuals
(Subjects 1 to 4) (Table S1) and partial in 2 (Subjects 5 and 6), one
individual (Subject 7) (Table S1) interrupted antiretroviral therapy
during follow-up.
Phenotypic susceptibility predictions by population and
deep genotyping
The median (IQR) deep sequencing coverage per base was 3938
(3130 – 6945) sequences at baseline and 3965 (3688 – 7091)
sequences at virological failure. Deep sequencing detected all
mutations found by population sequencing in all subjects, and
found additional mutations in 6 out of 7 individuals. (Table S1)
Additional mutations were congruent with the treatment history
and modified 5.2% of phenotypic susceptibility predictions overall
(Table S2), with no significant differences between interpretation
algorithms.
Deep sequencing provided limited additional genotypic infor-
mation at baseline relative to PS. Baseline DS changed the ANRS
predicted susceptibility of lopinavir/r and saquinavir/r from
sensitive to intermediate in subject 1 and the ANRS susceptibility
of darunavir/r from intermediate to resistant in subject 2 (Table
S1). In subject 7 (Table S1), however, the detection of minority
protease I54L and V82A mutants by deep sequencing in addition
to the I54I/V, T74S and L90M detected by population
sequencing, consistently decreased the virus susceptibility to
indinavir/r across the three algorithms, and led to decreases in
predicted susceptibility to saquinavir/r and darunavir/r and to
lopinavir/r by the HIVdb and Rega algorithms. The additional
detection of the reverse transcriptase M41L and T215Y mutants
in this individual led to decreases in susceptibility to different
NRTIs by the three algorithms.
Most additional resistance mutations leading to changes in
susceptibility predictions were found after virological failure to
deep salvage therapy (Table S1). Consistent decreases in etravirine
susceptibility were observed in the two subjects treated with
etravirine in this study (subjects 1 and 2). Detection of additional
mutations in protease in these two individuals also led to decreased
susceptibility to saquinavir/r and lopinavir/r in the ANRS
algorithm, respectively. Low-level K103N mutants were detected
at virological failure in subject 5. This individual had received
efavirenz in the past and was receiving nevirapine at baseline,
when he was switched from tenofovir, stavudine, lamivudine and
nevirapine, to tenofovir/emtricitabine, darunavir/r and enfuvir-
tide. The withdrawal of stavudine-mediated pressure over pre-
existing K103N mutants might have enabled their emergence and
subsequent detection at virological failure. Finally, the detection of
minority K219Q and T215Y mutants in subjects 6 and 7,
respectively, led to consistent decreases in predicted viral
susceptibility to different NRTIs.
Most baseline resistance mutations were lost in subject 7 during
treatment interruption becoming undetectable even by deep
sequencing at the time of virological failure. No changes in
predicted susceptibility were observed for tipranavir or raltegravir,
although detection of minority G140S in subject 3 suggested
improved fitness of the Q148R mutants detected by population
sequencing at virological failure (Table S1).
Discussion
While being technically non-inferior to population genotyping,
deep sequencing enabled the detection of additional resistance
mutations with potential clinical significance in 6 out of 7
individuals included in this study. Additional mutations, however,
only modified about 5% of antiretroviral susceptibility predictions,
including decreased etravirine efficacy in the 2 subjects developing
virological failure to this drug, and decreased NRTI, efavirenz and
indinavir/r efficacy in 2, 1, and 1 subject, respectively. Changes in
darunavir susceptibility observed in 2 individuals were not
consistent across algorithms. Deep sequencing had no impact on
susceptibility predictions for tipranavir or raltegravir.
Deep sequencing could modify patient clinical management by
avoiding drugs whose resistance may have been underestimated by
population sequencing. Indeed, baseline low-frequency PI-resis-
tant mutants were selected during treatment exposure in two
subjects: I54T in subject 1, and V32I, Q58E and L89V in subject
2. I54T is a PI-related mutation that appears to be associated with
decreased susceptibility to each of the PIs, although its effect has
not been well studied. Q58E is a non-polymorphic PI-related
mutation associated with reduced susceptibility tipranavir
[21,22,23] and possibly to several other PIs. Selection of I54T
and Q58E mutations during darunavir therapy may be explained
due to residual phenotypic or compensatory effect of such
mutations on darunavir susceptibility, genome colinearity with
other darunavir-associated mutations, or simple stochastic effects.
Interestingly, emergence of I54T in subject 1 was associated with
decay in I54A, indicating a possible fitness advantage of I54T over
I54A in this particular context. Conversely, substitutions V32I and
L89V are nonpolymorphic PI-selected accessory mutations which
emerge during treatment with darunavir/ritonavir. Both muta-
tions were associated with decreased response to darunavir/
ritonavir in the POWER trials [24], suggesting that they were
selected in subject 2 because they conferred additional resistance
to darunavir.
Most additional mutants in our study, however, were detected
at virological failure. Varghese et al. also detected additional
minority variants with major etravirine mutations only in patients
failing an NNRTI-containing regimen [14]. Taken together, these
results suggest that deep sequencing might be more useful to assess
loss of antiviral efficacy after virological failure than to screen for
pre-existing resistance in subjects with extensive treatment
exposure. As with population sequencing, deep sequencing should
also be performed immediately or shortly after virological failure.
The increased sensitivity of deep sequencing could also reassure
clinicians about the absence of additional genotypic resistance
when making clinical management decisions. This is particularly
important for the management of subjects with suboptimal
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genotypic information in all adherence strata. (Table S1, Table S2)
Deep sequencing, for example, confirmed virus susceptibility to
integrase strand-transfer inhibitors in 4 out of 5 subjects who
developed virological failure to raltegravir-including regimens,
indicating that raltegravir remained a suitable option for
subsequent salvage regimens. Similarly, deep sequencing con-
firmed that subjects 5, 6 and 7 could still be treated with a number
of different PIs and suggested higher virus susceptibility to
tipranavir than to darunavir in subject 7. (Table S2) The absence
of resistance mutations by deep sequencing, however, should be
interpreted with caution; the loss of most baseline mutants in
subject 7 during antiretroviral therapy interruption shows that
deep sequencing can also miss clinically relevant resistance
mutations present ,1% in the viral population.
Detection of low-frequency resistance mutations associated with
hypersusceptibility could also improve predicted susceptibility to
certain antiretrovirals. For example, the incorporation of a
minority T215F mutation in subject 2 changed the HIVdb
predicted susceptibility to tenofovir from ‘‘resistant’’ to ‘‘interme-
diate’’ at virological failure. Therefore, ultrasensitive genotyping
also has the potential to refine genotype interpretation rules
towards increased virus susceptibility.
Our findings extend those of Le et al. [15], who showed that deep
sequencing detected low-frequency mutations unrecognized by
Sanger sequencing in 19 out of 22 antiretroviral–experienced
individuals experiencing virological failure in routine HIV care
between 2004-2007. Additional minority mutants increased a
subject’s genotypic resistance to one or more antiretrovirals in 17 of
22 individuals (77%), correlated with the failing drugs in 21%
subjects, and with historical antiretroviral use in 79% subjects. In Le’s
study, however, samples were collected before etravirine, darunavir
or raltegravir became available, so the effect additional minority
mutants on HIV susceptibility to these drugs could not be evaluated.
The main limitations of our study are its small sample size, its
retrospective observational nature and the fact that adherence was
self-reported. This study makes two arguable assumptions: First, that
a mutant detected above 1% is clinically relevant. This threshold is
clearly above the PCR and 454 sequencing error found in our own
and other studies [14,25] and has been shown to predict virological
outcomes of first-line NNRTI therapy in treatment–naı ¨ve individu-
als.[2] Moreover, potential PCR-derived recombination should not
affect our findings because we did not evaluate mutational linkage.
The second assumption is that minority mutants have the same
weight in genotypic susceptibility interpretation algorithms as if they
were present at higher levels. While biologically plausible, formal
studies have not been developed to assess this assumption.
In conclusion, in this subset of heavily pre-treated individuals,
deep sequencing showed technical non-inferiority to population
sequencing. However, although additional mutations improved the
assessment of genotypic resistance to etravirine, deep sequencing
did not consistently provide additional information on darunavir,
tipranavir or raltegravir susceptibility relative to population
sequencing. Further studies should extend our findings and address
the clinical impact of ultrasensitive genotyping in HIV-1 infected
individuals experiencing virological failure to their first or second-
line antiretroviral therapy. Proper throughput escalation, sample
multiplexing and adequate sequence coverage may potentially turn
ultrasensitive genotyping into a feasible strategy for HIV drug
resistance management in the clinical setting.
Supporting Information
Table S1 Additional genotypic information provided by deep
HIV-1 sequencing and changes in predicted phenotypic suscep-
tibility, relative to population sequencing
a, b, c.
a Only mutations
with a score $ 5 in the Stanford HIV Drug Resistance Database
were included in the analysis.
b ART: antiretroviral therapy; DS:
deep sequencing; PI: protease inhibitor; NRTI: nucleoside reverse
transcriptase inhibitor; NNRTI: non-nucleoside reverse transcrip-
tase inhibitor; InSTI: Integrase Strand Transfer Inhibitor; ZDV:
zidovudine; ABC: abacavir; d4T: stavudine; ddI: didanosine;
TDF: tenofovir; EFV: efavirenz; NVP: nevirapine; ETR: etravir-
ine; ATV: atazanavir; IDVr: indinavir/ritonavir; FAPVr: fosam-
prenavir/ritonavir; SQVr: saquinavir/ritonavir; LPVr: lopinavir/
ritonavir; DRVr: darunavir/ritonavir; TPVr: tipranavir/ritonavir;
ANRS: algorithm of the French ANRS (Agence Nationale de Recherche
sur le SIDA) AC11 Resistance group, version 18, July 2009, France;
HIVdb: HIV db program version 6.0.8, implemented at the
Stanford HIV Drug Resistance Database, Stanford University,
USA; REGA: Algorithm of the Rega Institute version 8.0.2,
University of Leuven, Belgium.
c Predicted antiretroviral suscep-
tibility: S: susceptible; I: intermediate; R: Resistant.
(DOC)
Table S2 Predicted antiretroviral susceptibility according to
Sanger or quantitative deep 454 sequencing. Color code: Green=
Sensitive; Yellow=Intermediate; Red=Resistant. Changes in
predicted phenotypic susceptibility between Sanger and 454
sequencing sequencing are highlighted in black boxes. DLV:
delavirdine; EFV: efavirenz; ETR: etravirine; NVP: neviapine;
3TC: lamivudine; ABC: abacavir; AZT: zidovudine; d4T:
stavudine; ddI: didanosine; FTC: emtricitabine; TDF: tenofovir
dippivoxil fumarate; ATV: atazanavir; ATVr: ritonavir-boosted
atazanavir; DRVr: ritonavir-boosted darunavir; FPVr: ritonavir-
boosted fosamprenavir; IDVr: ritonavir-boosted indinavir; LPVr:
ritonavir-boosted lopinavir; NFV: nelfinavir; SQVr: ritonavir-
boosted saquinavir; TPVr: ritonavir-boosted tipranavir; RA:
ralegravirL; ELV: elvitegravir.
(XLS)
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